PAtient-CenTric Chronic Pancreatitis Registry (PACT-CP)

CorEvitas400 enrolled

Overview

The main objective of this study is to generate real-world evidence reflecting the experience of individuals with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP). Efforts will be directed toward understanding the unmet need and therapeutic burden to identify the most critical factors that influence treatment choices/prescribing patterns, quality of life, and healthcare utilization outcomes in standard of care for individuals with EPI due to CP.

Study participants will be followed prospectively, and data from study participants will be collected at 3-month intervals via Electronic Data Capture (EDC) portal. Investigators will complete assessments approximately every 6 months at the time of routine clinical encounters. Adverse Events (AEs) will be collected as part of the study data collection forms. Serious Adverse Events (SAEs) are to be reported within 24 hours (1 business day) of awareness, whether or not the site learns of the event at the time of a registry follow-up visit.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Chronic Pancreatitis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: To be eligible for enrollment, a study participant must meet the inclusion criteria below: 1. At least 18 years of age (or age of majority) 2. Willing to provide consent to participate 3. Meet one (1) of the following at the time of enrollment: 1. Diagnosis of chronic pancreatitis (CP) 2. Diagnosis of recurrent acute pancreatitis (RAP) 4. Suspected or confirmed diagnosis of EPI made by a healthcare provider 5. On Pancreatic Enzyme Replacement Therapy (PERT), either prior to the Enrollment Visit or newly prescribed at the time of the Enrollment Visit. To be eligible for enrollment into the registry, a study participant must not have any of the criteria below: 1. Currently participating in or planning to participate in a double-blind randomized trial and/or open-label Phase 3b/4 on CP or EPI 2. Diagnosed with any of the following conditions at the time of enrollment: 1. Cystic fibrosis 2. Fibrosing colonopathy 3. A history of or current diagnosis of pancreatic cancer, main duct papillary mucinous neoplasms (IPMNs), and other pancreatic malignancies 4. Allergy to pork or other porcine pancreatic enzyme products (PEPs) 5. Any condition that would, in the investigator's opinion, limit the individual's ability to complete the study. \- Exclusion Criteria: \-

Locations (1)

CorEvitas

Waltham, Massachusetts, United States

Outcomes

Primary Outcomes

Main Objective of the Study

The main objective of this study is real-world evidence reflecting the experience of individuals with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP).

Time frame: Up to 5 years

Creation of a Patient Cohort

Create a cohort of well-characterized patients with EPI due to CP research.

Time frame: Up to 5 years

Disease History and Progression Data at Initial Visit

Collect clinical data to characterize both the EPI due to CP disease history and disease progression at the initial visit.

Time frame: At Initial Visit

Progression Data (Every 3 months after Initial Visit)

Collect clinical data to characterize EPI due to CP disease progression every 3 months after the initial visit through a patient reported outcome (PRO).

Time frame: Every 3 months after Initial Visit up to 5 years

Progression Data (Every 6 months after Initial Visit)

Collect clinical data to characterize EPI due to CP disease progression every 6 months after the initial visit alongside the physician at the site.

Time frame: Every 6 months after Initial Visit up to 5 years

Clinical Care Practice Data at Initial Visit

Collect data on clinical care practices for participants with EPI to better understand the impact on outcomes at the initial visit.

Time frame: At Initial Visit

Clinical Care Practice Data (Every 3 months after Initial Visit)

Collect data on clinical care practices for participants with EPI to better understand the impact on outcomes every 3 months after the initial visit through a patient reported outcome (PRO).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.